Last Price
0.07
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Jonathan Mow Mr. Jonathan Mow
Full Time Employees: 60 60
IPO Date: 2018-10-18 2018-10-18
CIK: 0001169245 0001169245
ISIN: US7172241090 US7172241090
CUSIP: 717224109 717224109
Beta: 2.87 2.87
Last Dividend: 0.00 0.00
Dcf Diff: 1.42 1.42
Dcf: 2.42 2.42
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.